ERBB2 and inflammatory breast carcinoma: Moreover, the combination of an HDAC inhibitor (entinostat) with HER2 + targeted therapeutic agents (lapatinib and trastuzumab) significantly enhanced the apoptosis of trastuzumab-resistant IBC tumour cells in a preclinical model [75].